Skip to main content
Arsham Sheybani, MD, Ophthalmology, Saint Louis, MO

ArshamSheybaniMD

Ophthalmology Saint Louis, MO

Anterior Segment Related, Cataract Related, Glaucoma Related

Associate Professor, Ophthalmology & Visual Sciences, Washington University in St. Louis School of Medicine Residency Program Director; Fellowship Director, Glaucoma and Anterior Segment Surgery

Dr. Sheybani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sheybani's full profile

Already have an account?

  • Office

    4901 Forest Park Ave
    Fl 6
    Saint Louis, MO 63108
    Phone+1 314-362-3937
    Fax+1 314-362-3725

Education & Training

  • Washington University/B-JH/SLCH Consortium
    Washington University/B-JH/SLCH ConsortiumResidency, Ophthalmology, 2009 - 2012
  • Mercy Hospital (St Louis)
    Mercy Hospital (St Louis)Internship, Transitional Year, 2008 - 2009
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 2008

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 2012 - 2026
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • Nearly 20% of Glaucoma Surgeries for POAG Fail After 5 YearsFebruary 2022

Press Mentions

  • Iantrek Announces Publication Highlighting 12-Month Results for Its Bio-Interventional Uveoscleral Outflow Technology
    Iantrek Announces Publication Highlighting 12-Month Results for Its Bio-Interventional Uveoscleral Outflow TechnologyOctober 12th, 2024
  • Iantrek Announces 1-Year Clinical Results of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma Patients
    Iantrek Announces 1-Year Clinical Results of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma PatientsSeptember 17th, 2024
  • Open-Angle Glaucoma: Burden of Illness, Current Therapies, and the Management of Nocturnal IOP Variation
    Open-Angle Glaucoma: Burden of Illness, Current Therapies, and the Management of Nocturnal IOP VariationNovember 15th, 2019
  • Join now to see all